OssDsign AB Achieves Major Milestone with 10,000 Patients Treated in the US

Stockholm, Sweden, May 13, 2025 — OssDsign AB, a leading health care company specializing in medical devices for bone regeneration, has reached a significant milestone with its innovative product, OssDsign Catalyst. The company, based in Uppsala, Sweden, and listed on the Swedish Stock Exchange, has successfully treated 10,000 patients in the United States with its nanosynthetic bone graft.

Karolinska Development AB, a key investor in OssDsign, announced this achievement, highlighting the product’s rapid and robust bone formation capabilities, even in challenging, poorly vascularized environments. Since its launch in the US market in August 2021, OssDsign Catalyst has made a substantial impact in the orthobiologics sector, demonstrating its effectiveness and reliability.

The success of OssDsign Catalyst underscores the company’s commitment to advancing medical technology and improving patient outcomes. With a market capitalization of 1.37 billion SEK and a close price of 13.92 SEK as of May 8, 2025, OssDsign continues to show strong financial performance and growth potential.

As OssDsign prepares for its upcoming Annual General Meeting, stakeholders and investors are keenly observing the company’s trajectory. The milestone of treating 10,000 patients not only reflects the product’s success but also positions OssDsign as a formidable player in the global health care market.

With its innovative approach and proven track record, OssDsign AB is well-positioned to continue its expansion and influence in the medical device industry, promising further advancements and successes in the future.